Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Neuway Pharma GmbH. (8/18/15). "Press Release: Neuway Pharma GmbH Appoints Dr. Rudi Scherhag as Managing Director". Bonn.

Organisations Organisation Neuway Pharma GmbH
  Organisation 2 Boehringer Mannheim (Group)
  Today Roche Diagnostics GmbH
  Group Roche (Group)
Products Product drug delivery technology (drug formulation technology)
  Product 2 CNS drug
Persons Person Scherhag, Rudi (Neuway Pharma 201508– Managing Director before ImClone Systems + Heidelberg Pharma + Roche Mannheim)
  Person 2 Rapp, Stephan (Neuway Pharma GmbH 20140–201508 Managing Director)

NEUWAY Pharma announced today the appointment of Dr. Rudi Scherhag as Chief Operating Officer and Managing Director. Dr. Scherhag has extensive experience in managing various development projects from pre-clinical to registration in the pharmaceutical and biotech industry.

As planned, Dr. Scherhag will take over the managing director position from Dr. Stephan Rapp, who will focus on new projects and act as consultant and shareholder of NEUWAY.

Dr. Scherhag has made his most important professional step at Boehringer Mannheim/Roche, where he successfully managed the global development of its blockbuster product Epoetin beta. He also played a major role in the establishment of two companies. As a Member of the Executive Board at Heidelberg Pharma , Dr. Scherhag was responsible for project and business development. Before joining Neuway, he served as Managing Director at ImClone Systems International, a newly founded European clinical development organization of the US biotech company ImClone Systems Corp.

„We are glad to strengthen our team with Dr. Scherhag“, commented Dr. Heiko Manninga, Co-Founder, Chief Scientific Officer und Managing Director at NEUWAY. „With his experience he will provide significant contributions to the further development of our company. I am very much looking forward to working with him.“

Dr. Rainer Strohmenger, Chairman of NEUWAY’s advisory board and General Partner at Wellington Partners, added: „With his considerable experience and expertise in the field of drug and business development, I am convinced that Dr. Scherhag will make an important contribution to the success of NEUWAY’s innovative CNS drug delivery technology. On behalf of all shareholders, I thank Dr. Stephan Rapp for his outstanding work in developing NEUWAY. He leaves behind an excellently-positioned young biotechnology companies with exceptional potential.“

About NEUWAY Pharma

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

Further information
NEUWAY Pharma GmbH:
Press Contact:
Christine Kuhn, +49-(0)228-522198-15,

NEUWAY Pharma GmbH, Ludwig-Erhard-Allee 2, 53175 Bonn

Record changed: 2017-04-02


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Neuway Pharma GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top